Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-021880
Filing Date
2017-11-06
Accepted
2017-11-06 17:24:42
Documents
52
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q aimt-10q_20170930.htm 10-Q 1908583
2 EX-10.1 aimt-ex101_315.htm EX-10.1 111342
3 EX-31.1 aimt-ex311_6.htm EX-31.1 19469
4 EX-31.2 aimt-ex312_7.htm EX-31.2 19444
5 EX-32.1 aimt-ex321_9.htm EX-32.1 16899
  Complete submission text file 0001564590-17-021880.txt   5781416

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT aimt-20170930.xml EX-101.INS 1267848
7 XBRL TAXONOMY EXTENSION SCHEMA aimt-20170930.xsd EX-101.SCH 30005
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aimt-20170930_cal.xml EX-101.CAL 32734
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aimt-20170930_def.xml EX-101.DEF 90251
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE aimt-20170930_lab.xml EX-101.LAB 269373
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aimt-20170930_pre.xml EX-101.PRE 196533
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

EIN.: 452748244 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37519 | Film No.: 171180295
SIC: 2834 Pharmaceutical Preparations